The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tiplasinin     2-[1-benzyl-5-[4- (trifluoromethoxy)phenyl]...

Synonyms: Tiplaxtinin, PAI-039, CHEMBL325441, AG-F-38887, SureCN3052065, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tiplasinin

  • To investigate the effect of tiplaxtinin, designed as a synthetic inhibitor of plasminogen activator inhibitor-1 (PAI-1), on obesity, male C57Bl/6 mice (13-14 weeks old) were kept on a high-fat diet (20.1 kJ/g) for four weeks without or with addition of tiplaxtinin (PAI-039) at a dose of 2 mg/g food [1].
  • Although occlusive thrombosis was observed across all groups based upon the absence of measurable blood flow, a high incidence (>60%) of spontaneous reperfusion occurred only in those groups receiving PAI-039 [2].
  • In conclusion, PAI-039 is an orally active prothrombolytic drug that inhibits PAI-1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion [2].
  • In a model of diet-induced obesity, pair-fed C57 Bl/6 mice administered PAI-039 in a high-fat diet exhibited a dose-dependent reduction in body weight, epididymal adipose tissue weight, adipocyte volume, and circulating plasma active PAI-1 [3].
  • METHODS: Aged male wild-type (WT) or transgenic mice with adipose tissue overexpression of PAI-1 (45-55 weeks) in 50% C57Bl/6: 50% Friend Virus B-strain (FVB) genetic background, kept on normal chow, were used without or with administration of a synthetic low molecular weight PAI-1 inhibitor (PAI-039) to the food (1 mg g(-1)) for 4 weeks [4].

High impact information on Tiplasinin


Biological context of Tiplasinin


Anatomical context of Tiplasinin

  • Dogs received by oral gavage either vehicle (control) or the PAI-1 inhibitor PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid] (1, 3, and 10 mg/kg) and were subjected to electrolytic injury of the coronary artery [2].
  • In a tumor angiogenesis model, PAI-039 treatment of wild-type mice dose-dependently decreased hemoglobin concentration and endothelial cell staining within the Matrigel implant, indicating reduced angiogenesis, but exhibited no in vivo efficacy in PAI-1 null mice [6].
  • Objectives: We hypothesized that an orally active small molecule inhibitor of PAI-1 (PAI-039; tiplaxtinin) could affect smooth muscle cell (SMC) attachment and migration in vitro on a vitronectin matrix, and exhibit antiangiogenic activity in vivo [6].

Associations of Tiplasinin with other chemical compounds

  • Plasma glucose, triglycerides, and leptin were also significantly reduced in drug-treated mice, and concentrations of PAI-039 associated with these physiological effects were near the in vitro IC(50) for the inhibition of PAI-1 [3].

Gene context of Tiplasinin

  • Differentiation of human preadipocytes to adipocytes was associated with leptin synthesis, which was significantly reduced in the presence of PAI-039, together with an atypical adipocyte morphology characterized by a reduction in the size and number of lipid containing vesicles [3].

Analytical, diagnostic and therapeutic context of Tiplasinin

  • Previously PAI-039 has been shown to exhibit in vivo activity in various animal models, but the mechanism of inhibition is unknown [5].
  • Spontaneous reperfusion in the 10 mg/kg PAI-039 group accounted for total blood flow (area under the curve of coronary blood flow) of 99.6 +/- 11.7 ml after initial thrombotic occlusion (p < 0.05 compared with control) [2].


  1. Tiplaxtinin impairs nutritionally induced obesity in mice. Lijnen, H.R., Alessi, M.C., Frederix, L., Collen, D., Juhan-Vague, I. Thromb. Haemost. (2006) [Pubmed]
  2. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. Hennan, J.K., Elokdah, H., Leal, M., Ji, A., Friedrichs, G.S., Morgan, G.A., Swillo, R.E., Antrilli, T.M., Hreha, A., Crandall, D.L. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  3. Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1. Crandall, D.L., Quinet, E.M., El Ayachi, S., Hreha, A.L., Leik, C.E., Savio, D.A., Juhan-Vague, I., Alessi, M.C. Arterioscler. Thromb. Vasc. Biol. (2006) [Pubmed]
  4. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. Lijnen, H.R., Alessi, M.C., Van Hoef, B., Collen, D., Juhan-Vague, I. J. Thromb. Haemost. (2005) [Pubmed]
  5. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. Gorlatova, N.V., Cale, J.M., Elokdah, H., Li, D., Fan, K., Warnock, M., Crandall, D.L., Lawrence, D.A. J. Biol. Chem. (2007) [Pubmed]
  6. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. Leik, C.E., Su, E.J., Nambi, P., Crandall, D.L., Lawrence, D.A. J. Thromb. Haemost. (2006) [Pubmed]
WikiGenes - Universities